Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: Results from a multicentre randomized clinical study

HIV Medicine

Volumn 13, Issue 5, 2012, Pages 291-296

  Routy, J P ^a   Tremblay, C L ^b   Angel, J B ^c   Trottier, B ^d   Rouleau, D ^b   Baril, J G ^b   Harris, M ^e   Trottier, S ^f   Singer, J ^g   Chomont, N ^h   Sekaly R P ^b,h   Boulassel, M R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Clinique Medicale l'Actuel   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g ST PAUL S HOSPITAL   (Canada)

^h VGTI Florida   (United States)

Author keywords

CD4 T cells; Highly active antiretroviral therapy; HIV; Reservoir; Valproic acid

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CARRIER; DRUG DOSE INCREASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 RESERVOIR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VALPROIC ACID; VIRAL LOAD; VIRUS LATENCY;

EID: 84859424538     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00975.x     Document Type: Article

References (21)

1. Chun TW, Justement JS, Murray D etal. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24: 2803-2808.
2. Finzi D, Hermankova M, Pierson T etal. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
3. Siliciano JD, Kajdas J, Finzi D etal. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-728.
4. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, NF-kappa GWC. B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25: 139-149.
5. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep 2010; 7: 37-43.
6. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81: 10914-10923.
7. Demonté D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 2004; 68: 1231-1238.
8. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-1108.
9. Lehrman G, Hogue IB, Palmer S etal. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366: 549-555.
10. Routy JP. Valproic acid: a potential role in treating latent HIV infection. Lancet 2005; 366: 523-524.
11. Steel A, Clark S, Teo I etal. No change to HIV-1 latency with valproate therapy. AIDS 2006; 20: 1681-1682.
12. Siliciano JD, Lai J, Callender M etal. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195: 833-836.
13. Sagot-Lerolle N, Lamine A, Chaix ML etal. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22: 1125-1129.
14. Archin NM, Eron JJ, Palmer S etal. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22: 1131-1135.
15. Archin NM, Cheema M, Parker D etal. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 2010; 5: e9390.
16. Boulassel MR, Mercier F, Gilmore N, Routy JP. Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects. Clin Immunol 2007; 124: 149-157.
17. Tremblay CL, Giguel F, Merrill DP etal. Marked differences in quantity of infectious human immunodeficiency virus type 1 detected in persons with controlled plasma viremia by a simple enhanced culture method. J Clin Microbiol 2000; 38: 4246-4248.
18. Coiras M, López-Huertas MR, Pérez-Olmeda M, Alcamí J. Understanding HIV latency provides clues for the eradication of long-term reservoirs. Nat Microbiol 2009; 7: 798-812.
19. Gandhi RT, Bosch RJ, Aga E etal. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201: 293-296.
20. Gandhi RT, Zheng L, Bosch RJ etal. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: e1000321.
21. Chomont N, El-Far M, Ancuta P etal. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.